China Pharma Holdings (CPHI) Interest & Investment Income (2010 - 2026)
China Pharma Holdings' (CPHI) quarterly Interest & Investment Income came in at $147.0 in Q1 2026, down 86.31% YoY from $1074.0 in Q1 2025, and down 30.99% on a QoQ basis from $213.0 in Q4 2025.
China Pharma Holdings (CPHI) Interest & Investment Income (2010 - 2026) Analysis & Trends
China Pharma Holdings (CPHI) has 17 years of Interest & Investment Income data on file, last reported at $147.0 in Q1 2026.
- Quarterly Interest & Investment Income fell 86.31% year-over-year to $147.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1076.0 (down 80.07% YoY) and the FY2025 annual result came in at $2003.0, down 69.84% from the prior year.
- Interest & Investment Income eased to $147.0 in Q1 2026, from $213.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $6655.0 in Q1 2022 to a low of $147.0 in Q1 2026.
- A 5-year average of $1538.1 and a median of $1240.0 in 2022 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2022 — Interest & Investment Income surged 1539.16% — and 2026, when it sank 86.31%.
- Tracing CPHI's Interest & Investment Income over 5 years: stood at $1003.0 in 2022, then soared by 152.24% to $2530.0 in 2023, then sank by 47.23% to $1335.0 in 2024, then tumbled by 84.04% to $213.0 in 2025, then tumbled by 30.99% to $147.0 in 2026.
- The last three Interest & Investment Income figures came in at $147.0 (Q1 2026), $213.0 (Q4 2025), and $294.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | 154.39 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 31.50 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 12.40 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | China Pharma Holdings | 41.34 Mn | 41.03 Mn | 83,566.00 | 81.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 147.00 |
| Dec 31, 2025 | 213.00 |
| Sep 30, 2025 | 294.00 |
| Jun 30, 2025 | 422.00 |
| Mar 31, 2025 | 1,074.00 |
| Dec 31, 2024 | 1,335.00 |
| Sep 30, 2024 | 1,460.00 |
| Jun 30, 2024 | 1,531.00 |
| Mar 31, 2024 | 2,315.00 |
| Dec 31, 2023 | 2,530.00 |
| Sep 30, 2023 | 2,182.00 |
| Jun 30, 2023 | 942.00 |
| Mar 31, 2023 | 948.00 |
| Dec 31, 2022 | 1,003.00 |
| Sep 30, 2022 | 1,857.00 |
| Jun 30, 2022 | 1,240.00 |
| Mar 31, 2022 | 6,655.00 |
| Dec 31, 2021 | 1,412.00 |
| Sep 30, 2021 | 638.00 |
| Jun 30, 2021 | 579.00 |